SCHEMBL21200404

SCHEMBL21200404

Cn1cnnc1C(F)(F)C(C)(F)c1cccc(N)c1

nearest known ligand 0.54

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ CBLB Q13191 19/20 0.54
▸ TSHR P16473 1/20 0.42
▸ MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29867551 1.00 CBLB (0.54) CBLBTSHRMAPK1
SCHEMBL21200402 1.00 CBLB (0.54) CBLBTSHRMAPK1
SCHEMBL29626771 1.00 CBLB (0.54) CBLBTSHRMAPK1
SCHEMBL21200737 1.00 CBLB (0.54) CBLBTSHRMAPK1
SCHEMBL29626732 1.00 CBLB (0.54) CBLBTSHRMAPK1
SCHEMBL28741983 0.78 CBLB (0.49) CBLB
SCHEMBL21200198 0.77 CBLB (0.66) CBLB
SCHEMBL29841601 0.76 CBLB (0.56) CBLBTSHRMAPK1
SCHEMBL29841599 0.76 CBLB (0.56) CBLBTSHRMAPK1
SCHEMBL21201026 0.74 CBLB (0.46) CBLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022221704-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER HOTSPOT THERAPEUTICS, INC. (US) 2022-10-20 — — WO disclosed
WO-2021021761-A1 UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION NURIX THERAPEUTICS, INC. (US) 2021-02-04 — — WO disclosed
EP-3743063-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF Nurix Therapeutics, Inc. (US) 2020-12-02 — — EP disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
WO-2019148005-A1 INHIBITORS OF CBL-B AND METHODS OF USE THEREOF NURIX THERAPEUTICS, INC. (US) 2019-08-01 — — WO disclosed
Send feedback